A brief post noting retatrutide hits GIP, GLP-1 and glucagon receptors in one weekly shot. The poster calls phase 3 data strong, with no approval yet.
Recap by typeshit. Post by @dilaudiddaddy_ on Instagram.
Kalkine Media ties the attention on Lilly to orforglipron's progress, arguing a pill could scale cheaper than injectables and ease supply limits.
Smaller portions could become more common on shelves, with inflation and GLP-1 appetite changes both pushing food makers toward personal packs.
Chokshi notes the sales were 0.4% of Lilly's $23 billion quarter, and that Divi's Labs hasn't announced any role in making the drug.
Oral Wegovy brought in about $850 million in H1 2026 and holds over 80% of new US oral scripts. Lilly says Foundayo volume doubled in a month.
A short note on the unapproved triple agonist shot advises telling your anesthesia team before surgery because of how it slows digestion.
The Facebook post says the triple-agonist shot slows stomach emptying, which can be risky under anesthesia. It also notes the drug has no FDA approval yet.
Loading…